Drug Profile
Adalimumab biosimilar - Coherus BioSciences
Alternative Names: adalimumab-aqvh; CHS-1420; YUSIMRYLatest Information Update: 06 Jul 2023
Price :
$50
*
At a glance
- Originator Coherus Biosciences
- Developer Coherus BioSciences
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antineoplastics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Hepatoprotectants; Immunotherapies; Nootropics; Skin disorder therapies
- Mechanism of Action Immunosuppressants; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Plaque psoriasis
Highest Development Phases
- Marketed Ankylosing spondylitis; Crohn's disease; Juvenile rheumatoid arthritis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis